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Bacterial sepsis triggers robust activation of the complement system
with subsequent generation of anaphylatoxins (C3a, C5a) and the
terminal complement complex (TCC) that together contribute to
organ failure and death. Here we tested the effect of RA101295, a
2-kDa macrocyclic peptide inhibitor of C5 cleavage, using in vitro
whole-blood assays and an in vivo baboon model of Escherichia coli
sepsis. RA101295 strongly inhibited E. coli-induced complement ac-
tivation both in vitro and in vivo by blocking the generation of C5a
and the soluble form of TCC, sC5b-9. RA101295 reduced the E. coli-
induced “oxidative burst,” as well as leukocyte activation, without
affecting host phagocytosis of E. coli. RA101295 treatment reduced
plasma LPS content in E. coli-challenged baboons, implying reduced
complement-mediated bacteriolysis, whereas treated animals showed
slightly improved bacterial clearance during the bacteremic stage
compared with controls. Treatment with RA101295 also improved
consumptive coagulopathy and preserved endothelial anticoagulant
and vascular barrier functions. RA101295 abolished sepsis-induced
surges in proinflammatory cytokines and attenuated systemic circula-
tory and febrile responses, likely reflecting decreased systemic levels
of LPS and C5a. Overall, RA101295 treatment was associated with
significant organ protection and markedly reduced mortality com-
pared with nontreated controls (four of five animals survived in a
100% lethal model). We therefore conclude that inhibition of
C5 cleavage during the bacteremic stage of sepsis could be an impor-
tant therapeutic approach to prevent sepsis-induced inflammation,
consumptive coagulopathy, and subsequent organ failure and death.
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Severe sepsis is a life-threatening systemic condition for which,besides intravenous antibiotics, there are no specific targeted
therapies. Evidence from patients and animal models suggest
that sepsis is a multistage, multifactorial disease in which early
fulminant inflammatory responses to invading bacteria leads to
hypoperfusion and ischemia-reperfusion injury that develops
into multiple organ failure and death (1, 2). In its fulminant
form, Escherichia coli infection is characterized by high bacterial
load, especially in the very young and very old, and can produce
circulatory collapse and death within hours. This variant of sepsis
occurs in ∼15% of diagnosed patients. Sepsis is accompanied by
robust activation of the coagulation (3, 4) and the complement
(5) systems, triggered both by the pathogen itself and by dam-
aged tissue. Whereas local and controlled activation of these
pathways can promote host defense against pathogens, excessive
or uncontrolled systemic activation is harmful (5, 6). The end
products of complement activation are the anaphylatoxin C5a
and the C5b-9 terminal complement complex, which inserts into
membranes as the membrane attack complex and lyses bacteria
or promotes inflammation at a sublytic level. The terminal com-
plement complex formed in the fluid-phase, sC5b-9, is nonlytic and
a marker of plasma complement activation. C5b-9 and C5a are
major contributors to cell death, immune paralysis, cardiac dys-
function, and multiple organ failure (6, 7). C5a is a chemoattractant
signal to neutrophils and other inflammatory cells, and exerts ef-
fects on various cell types, contributing to apoptosis, immune pa-
ralysis, activation of the coagulation and fibrinolytic systems, and
multiorgan dysfunction (6). Besides lysis of bacteria, C5b-9 can
damage the cells and tissues of the host. It can induce tissue factor
activity on endothelial cells (8), and prothrombinase formation on
platelets (9, 10) and endothelial cells (11), thus contributing to
development of multiple organ failure (12). Activation of comple-
ment, inflammation, and coagulation together promote thrombo-
cytopenia and disseminated intravascular coagulation (DIC), a
potential lethal thrombo-hemorrhagic complication of sepsis (13).
Although inhibition of complement activation has been
entertained for decades as a potential therapy for septic patients
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(reviewed in ref. 14), it is not yet clear which component might
be the best target. There is also uncertainty regarding the opti-
mal timing of such intervention to achieve maximum protection
against complement-induced tissue damage, without compro-
mising beneficial antimicrobial and tissue recovery effects. Pre-
viously, we successfully prevented multiple organ failure by
blocking complement activation with a C3 inhibitor during the
late stage of disease, and markedly improved blood pressure
when we targeted early-stage events (15). However, blocking
complement activation at the C3 level is considered unsafe be-
cause the activation fragments C3b and iC3b are required for
bacteria opsonization and subsequent phagocytosis. We have
shown that E. coli clearance in vitro in porcine whole blood was
substantially reduced using a C3 inhibitor (16). Inhibition of
C5 activation has been investigated primarily in rodent models
(14) and a single statistically underpowered primate study (17).
The studies on rodents assumed that inhibition of C5a, rather
than C5, offers a better treatment strategy, as C5b and down-
stream C5b-9 are thought to have protective roles in lysing
bacteria (6). However, other studies in rodents have suggested
that both C5a and C5b-9 may not be absolutely required for host
defense, because C5-deficient mice (7) or C5 inhibition in rats
(18) were still protected against cecal ligation and puncture
(CLP)-induced sepsis. Furthermore, C6-deficient rats that were
able to form C5a, but not C5b-9, were also protected in the same
CLP model (18), suggesting that C5b-9 is the primary contributor
to sepsis-induced organ damage and death, and that it can be
inhibited without major compromise of immune effector function.
Well aware that mice are not men (19), translation from rodents to
humans has its limitations. Pig models of complement inhibitory
therapy in sepsis, in particular in combination with anti-CD14 (20–
22), have yielded promising results. They are more relevant to human
pathophysiology than rodent models, but the treatment was limited
to only 8 h, as the animals were monitored under full anesthesia.
Nonhuman primate studies are more clinically relevant and do not
suffer from the same very small experimental treatment windows.
Here we have used a well-established baboon model of E. coli
sepsis (2), coupled with in vitro whole-blood approaches, to test
the protective effects of an inhibitor of C5 cleavage, RA101295,
against sepsis-induced organ damage, and to determine whether
C5 inhibition provides a survival benefit. Our data demonstrate
that blockade of C5 in animals challenged with lethal doses of
E. coli markedly improved survival by reducing the lysis of bacteria
and the subsequent massive release of LPS, resulting in substantially
reduced coagulopathy and organ damage. RA101295 treatment did
not significantly impair host innate immune defense and clearance
of the pathogen. C5 inhibition with RA101295 prevented death of
four of five baboons exposed to a dose of bacteria that reproducibly
leads to 100% lethality in untreated animals.
Results
Effect of RA101295 on Complement Activation in a Human Whole-
Blood Assay. The effect of RA101295 on complement activation
was studied in vitro by incubating human whole blood anti-
coagulated with the thrombin inhibitor lepirudin (23) for 30 min
either with PBS (control), E. coli (5 × 107 cfu/mL), or LPS
(500 ng/mL) in the presence or absence of 1 μMRA101295 (Fig. 1).
RA101295 efficiently blocked sC5b-9 (Fig. 1A) and C5a (Fig. 1B)
generation induced by E. coli or LPS in human whole blood.
Baboon whole blood was also incubated with E. coli and RA101295,
as above (pretreatment), or addition of RA101295 was delayed by
5, 15, 30, or 60 min. The results show that RA101295 inhibited
E. coli-induced C5b-9 generation in a time-dependent manner
(Fig. S1). Even when the treatment was delayed by 1 h, the inhib-
itory effect was still robust (approximately 50%), suggesting that
posttreatment with RA101295 may be a viable therapeutic option.
RA101295 fully inhibited deposition of C5b-9 induced via classic,
alternative, or lectin pathways (Fig. 1 C–E) (24).
To determine the differential effect of complement inhibition
at the C3 vs. C5 levels, we incubated human whole blood, pre-
incubated with the C3 inhibitor compstatin or the C5 blocking
peptide RA101295, with E. coli. The C3 and C5 inhibitors were
equally effective in blocking the E. coli-induced oxidative burst
both in neutrophils and monocytes (Fig. 1F). The C3 and C5
inhibitors also decreased LPS release to a similar extent, consis-
tent with reduced complement-mediated bacteriolysis (Fig. 1G).
However, inhibition of C3, but not C5, substantially impaired
phagocytosis of E. coli by neutrophils and monocytes (Fig. 1H),
suggesting that formation of C3b/C3bi opsonins are required for
E. coli clearance by blood leukocytes.
Drug Exposure and Efficacy of RA101295 After Subcutaneous Injection
in Baboons. To determine the in vivo efficacy of RA101295, the
drug was administered via subcutaneous injection, at 10 mg/kg
body weight, and blood samples were collected in lepidurin an-
ticoagulant at 1, 2, 4, 6, 8, and 24 h postinjection. The amount of
RA101295 available in plasma indicated that the half-life of the
compound is ∼4 h (Fig. S2A). To determine the duration of
complement blockade, we determined plasma complement levels
Fig. 1. Effect of RA101295 on E. coli-induced complement activation, oxi-
dative burst, LPS release, and phagocytosis in whole blood in vitro assays.
Lepirudin-anticoagulated whole blood was incubated with or without 1 μM
RA101295 for 20 min, then 5 × 107 E. coli/mL or 500 ng/mL LPS was added for
30 min. RA101295 inhibits E. coli or LPS-induced complement activation as
shown by soluble C5b-9 (A) and C5a (B). Data are presented as mean ± SEM
(n = 3); multiple comparisons were made by one-way ANOVA with Bonferroni
post hoc test. *P < 0.05, **P < 0.01, ***P < 0.001. (C–E) The effect of
RA101295 on the classic (C), alternative (D), and lectin (E) pathways of
complement activation were examined in Lepirudin-anticoagulated plasma.
RA101295 completely attenuates complement activation on all three path-
ways. Data are presented as mean ± SEM (n = 3); two-tailed Student t test.
***P < 0.001. (F) Whole blood was incubated with 1 μM RA101295 or
0.2 mg/mL compstatin for 20 min, then with E. coli for 30 min. Oxidative
burst was determined using DHR123 dye. (G) Whole blood was incubated
with RA101295 or compstatin before E. coli incubation. Plasma was collected
and, to differentiate the LPS-mediated effect with other TLR4 ligands, in one
set polymyxin B (10 μg/mL) was added. LPS content in plasma was quantified
using HEK-blue TLR4 reporting cells. (H) Phagocytosis in the presence of
compstatin or RA101295 was determined using FITC-labeled E. coli. Data
shown in F and G are presented as mean ± SEM (n = 3); multiple comparisons
were made by one-way ANOVA followed by Bonferroni post hoc test: *P <
0.05, **P < 0.01, ***P < 0.001.



























by measuring C5b-9 levels after in vitro incubation with bacterial
peptidoglycan (PGN), a robust activator of complement (9) (Fig.
S2B), or using a hemolytic assay (Fig. S2C). Both assays showed
that RA101295 reached maximum inhibitory levels after 1 h
postinjection, provided full C5 inhibition during the first 8 h, and
∼90% inhibition at 24 h (Fig. S2 B and C).
Effects of RA101295 on Complement Activation Products in Vivo.
E. coli infusion induced rapid activation of the complement sys-
tem in vivo: C3b (Fig. 2A), C5a (Fig. 2B), and sC5b-9 (Fig. 2C)
reached maximal levels as early as 2 h postchallenge. Immunos-
taining of kidney sections showed substantial deposition of C3b
and C5b-9 in the kidney tubules (Fig. 2D), a typical feature of
kidney damage (25). RA101295 administered as four subcutane-
ous injections at 8-h intervals provided potent inhibition of sepsis-
induced complement activation for ∼48 h, as shown by plasma
levels of C5a and sC5b-9 (Fig. 2 B and C). The treatment also
reduced C3 activation, as shown by C3b levels (Fig. 2A), especially
during the early, highly bacteremic stage. Moreover, C3b and C5b-
9 immunostaining in kidney was abrogated in the presence of
RA101295 (Fig. 2D), suggesting decreased complement activation
in the treated group.
In contrast to the RA101295-treated group, nontreated ani-
mals became terminally ill and were humanely killed no later
than 36 h; therefore, there are no control plasma samples for late
time points (48, 72, and 168 h postchallenge) in all biomarkers
assays assessed in this study.
Effect of RA101295 on Sepsis-Induced Cytokine Inflammation.
Although E. coli sepsis strongly induced the expression of the
proinflammatory cytokines IL-6, IL-8, MCP-1, and TNF, treatment
with RA101295 lead to a substantial inhibition of these cytokines
(Fig. 3).
Effects of RA101295 on Sepsis-Induced Coagulopathy/DIC. E. coli
challenge in baboons is known to lead to pronounced activation
of the coagulation and fibrinolytic systems (26). Treatment with
RA101295 lead to decreased activated partial thromboplastin
time (APTT) (Fig. 4A), reduced consumption of plasma Factor
XII (Fig. 4B), and lower levels of Factor XIa-antithrombin
complexes (Fig. 4C), together supporting decreased activation
of coagulation via the intrinsic pathway. Moreover, RA101295-
treated animals showed decreased partial thromboplastin time
(PT) (Fig. 4D), lower expression of tissue factor mRNA (Fig. 4E),
and lower levels of Factor VIIa–antithrombin complexes (Fig. 4F),
all supporting a reduced activation of the tissue factor-dependent
extrinsic pathway of coagulation in RA101295-treated vs. untreated
animals. Accordingly, thrombin–antithrombin (TAT) complexes
were significantly decreased at 8 h in the treated animals compared
with untreated controls (Fig. 4G).
Fibrinogen consumption was slightly delayed in the treated group
and recovered after 48 h to reach baseline levels at 7 d postchallenge
(Fig. 4H). Furthermore, plasma levels of the fibrinolysis biomarkers,
tissue plasminogen activator (Fig. 4I), plasminogen activator in-
hibitor 1 (PAI-1) (Fig. 4J), and plasmin–antiplasmin complex (PAP)
(Fig. 4K) were significantly reduced in the treated vs. untreated
group. Taken together, these findings support decreased coagulo-
pathic and fibrinolytic responses to E. coli challenge in the
RA101295-treated group, suggesting a substantial protection against
DIC. Concordantly, fibrinogen/fibrin degradation products (FDP)
Fig. 2. Complement activation in plasma and kidney biopsies of baboons challenged with E. coli with/without RA101295. Complement activation products
were quantified in plasma samples: (A) soluble C3b, (B) C5a, (C) C5b-9. Data are presented as mean ± SEM (n = 5 per group). Same time-point data are
compared between LD100 and LD100+RA101295 using two-tailed Student t test. *P < 0.05, **P < 0.01, ***P < 0.001. (D) Immunostaining for C3b (green) and
C5b-9 (red) in the kidney of septic baboons (LD100; Upper) and septic baboons treated with C5 inhibitor (LD100+RA101295; Lower). To facilitate recognition
of microscopical structures, nuclear staining (blue) was included. Right column shows merged green and red channels; colocalization of C3b and C5b9 staining
is shown as yellow. (Scale bars, 50 μm.)
Fig. 3. Effect of RA101295 treatment on the time-course production of
cytokines during E. coli sepsis. (A) IL-6, (B) IL-8, (C) MCP-1, and (D) TNF in
plasma of septic baboons treated with or without RA101295. Data are
presented as mean ± SEM (n = 5 per group). Same time-point data are
compared between LD100 and LD100+RA101295 using two-tailed Student
t test: *P < 0.05, **P < 0.01, ***P < 0.001.
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(Fig. 4L) and D-dimer (Fig. 4M) levels were lower in the treated
vs. untreated group, suggesting decreased fibrin formation and
degradation.
Effects of RA101295 on Hematologic Parameters. E. coli sepsis lead
to a gradual decrease of hematocrit (Fig. 5A) and in red blood
cell (RBC) count (Fig. 5B). RA101295 treatment slightly re-
duced RBC consumption during the first 24 h. Hematocrit and
RBC count continued to decrease after cessation of the treat-
ment (T+36 h) and in the absence of visible intravascular he-
molysis, and had not recovered by the end of the experiment,
at 7 d.
E. coli infusion induced a steady decline of platelets (Fig. 5C).
Platelet consumption was similar between the two groups during
the first 24 h. Platelet consumption continued in the treated
group up to 72 h, but had fully recovered at 7 d. Immunostaining
of blood smears collected during the bacteremic state revealed
the presence of C3b on circulating RBC and platelet aggregates,
some of which were associated with bacteria (Fig. S3), suggesting
that platelets and bacteria may be opsonized and both cleared by
blood and tissue phagocytes.
E. coli infusion induced a rapid fall in white blood cell (WBC)
count, reaching the lowest values at 2 h, then slowly increasing (Fig.
5D). RA101295 treatment did not protect against sepsis-induced
leukopenia during the first 8 h but WBC count fully recovered after
48–72 h. Plasma levels of myeloperoxidase (Fig. 5E) and soluble
intercellular adhesion molecule 3 (ICAM3) (Fig. 5F), two proteins
released upon neutrophil activation, were decreased in the treated
group. Similarly, the increase in neopterin (Fig. 5G), released by
activated macrophages, was much reduced in the treated group.
Taken together, these data demonstrate that C5 blockade leads to
an overall inhibition of leukocyte activation.
Effect of RA101295 on Bacteriolysis, LPS Release, and Bacteria Clearance.
LPS in plasma was quantified using a reporter cell assay that
measure LPS-mediated signaling via the NF-κB pathway.
Quenching of LPS signaling with polymyxin B was used to differ-
entiate between the specific effects of LPS vs. other NF-κB ago-
nists. Baboons treated with RA101295 had a significantly lower
plasma LPS than nontreated septic controls (Fig. 6A), consistent
with decreased bacteriolysis. RA101295 did not impair, but slightly
increased the clearance of bacteria from blood (Fig. 6B), particu-
larly after 8 h postchallenge. Staining for lipid A showed lower
amounts of LPS associated with lung tissue (Fig. 6 C and D) in
animals treated with RA101295 vs. untreated septic animals.
Effects of RA101295 on Vital Signs and Organ Function in E. coli-
Challenged Baboons. Compared with nontreated septic baboons,
RA101295-treated animals had slightly improved vital signs while
under anesthesia (T0 to T+8), as reflected by heart and respiration
function, including heart and respiration rates, mean systemic ar-
terial pressure, oxymetry, and body temperature (Fig. S4). Treated
animals showed maintenance of plasma total proteins and albumin
levels, indicating reduced capillary leak, and intact endothelial
barrier function (Fig. 7 A and B). Plasma lactate was lower in the
RA101295-treated animals, suggesting enhanced vascular perfu-
sion and clearance of anaerobic metabolites (Fig. S5A). Creatinine
and blood urea nitrogen (BUN) biomarkers showed improved
kidney function during the treatment period (0–48 h), with addi-
tional improvement at 72 h and full recovery at 7 d (Fig. S5 B and
C). Liver transaminases were increased during the first 24–48 h but
partially recovered at 7 d (Fig. S5D). Marker of hepatocyte syn-
thetic activities ITIH4, a positive active-phase protein produced by
the liver (27), was substantially increased in the nontreated animals
but was undetectable in RA101295-treated animals, reflecting both
decreased liver inflammation and systemic inflammation (Fig. 7C).
Fig. 4. Effect of RA101295 treatment on hemostatic biomarkers. Time
course of: (A) APTT, (B) total Factor XII protein, (C) Factor XIa-antithrombin
(FXIa-AT) complexes, (D) PT. (E ) tissue factor mRNA, (F ) Factor VIIa-
antithrombin complexes (FVIIa-AT), (G) TAT complexes, (H) fibrinogen, (I) tis-
sue plasminogen activator (t-PA); (J) PAI-1, (K) PAP, (L) FDP, and (M) D-dimer in
septic baboons treated with or without RA101295. Data are presented as
mean ± SEM (n = 5 per group); Same time-point data are compared between
LD100 and LD100+RA101295 using two-tailed Student t test: *P < 0.05, **P <
0.01, ***P < 0.001.



























Effect of RA101295 on Markers of Endothelial Cell Dysfunction. De-
tection in plasma of proteins exposed on the endothelial cell
surface or secreted in response to inflammatory stimuli are
established markers of endothelial activation and dysfunction.
We observed a significant decrease in plasma levels of soluble
urokinase receptor (uPAR) (Fig. 7D), thrombomodulin (Fig.
7E), and angiopoietin-2 (Fig. 7F) in plasma of RA101295-treated
vs. nontreated baboons, suggesting that C5 inhibition protects
the endothelium against sepsis-induced injury.
Effect of RA101295 Against Sepsis-Induced Multiple Organ Failure.
Unbiased semiquantitative histological analysis of organs collected
at killing confirmed that RA101295 provided organ protection.
Unlike the nontreated group, RA101295-treated animals showed
near normal microscopic anatomy of the lung, liver, kidney, spleen,
and adrenals (Fig. 8A). The scoring of histological lesions showed
no detectible microvascular thrombosis, decreased capillary leakage,
no detectible leukocyte infiltration, and no detectible tissue necrosis
in the above organs (Fig. 8B).
There is a significant time difference between the samples taken
from the nontreated animals, killed after 24–36 h (for ethical
reasons), and those taken from treated animals, killed at 7 d.
Direct comparison of the histopathological features at time-points
after 36 h was thus not possible; as well as raising additional
ethical questions, to do so would have required substantially in-
creasing the number of animals used.
Effect of RA101295 on Sepsis-Induced Mortality. Treatment with
RA101295 provided a marked survival benefit, with four of five
treated animals reaching the 7 d end-point, compared with 100%
mortality in the five control animals challenged with the same
dose of bacteria (1010 cfu/kg) (Mantel–Cox test P = 0.0018; the
result is significant at P < 0.005) (Fig. 9). Based on our previous
experience with this LD100 model, animals that survive 7 d are
considered permanent survivors (2).
Discussion
We have used a well-established model of Gram-negative bac-
teria sepsis to test the therapeutic potential of a macrocyclic
peptide RA101295 that blocks C5 activation and thus the gen-
eration of C5a and C5b-9. Treatment with this C5 inhibitor:
(i) blocked sepsis-induced inflammation, (ii) attenuated sepsis-
induced coagulopathy, (iii) preserved endothelial function,
(iv) decreased leukocyte activation, (v) reduced the lysis of bac-
teria in the systemic circulation and the subsequent massive re-
lease of LPS, and (vi) did not affect the clearance of bacteria by
phagocytosis. C5 inhibition was associated with organ protection
and significantly reduced mortality in animals challenged with a
reproducibly lethal dose of E. coli.
Sepsis in the clinical setting is a complex multifactorial syn-
drome that presently cannot be fully recapitulated by a single
animal model. Our group has developed nonhuman primate
models of sepsis, where the intravenous challenge with defined
doses of pathogen can produce the various pathophysiologic
syndromes observed in clinical practice (2). Here we have used a
model of severe sepsis that mimics the progression of shock with
DIC in humans to test a therapy targeting the terminal pathway
of complement activation. Using this approach, we observed a
blunting of the early inflammatory response and DIC-induced by
Gram-negative LPS-containing bacteria, as well as reduced is-
chemia-reperfusion–associated tissue injury occurring during late
sepsis that leads to multiple organ failure and death (2).
Baboons were challenged by intravenous infusion of 1010cfu/kg
live E. coli, a dose that in our hands reliably leads to 100% mor-
tality. The model mimics the clinical variant of fulminant sepsis
with Gram-negative bacteria, which is the most deadly form of the
disease (2). This LD100 model results in rapid and severe in-
flammation, complement activation, and coagulopathy, leading to
irreversible shock and death within 24–36 h postchallenge (2).
During the bacteremic stage, which lasts ∼6–8 h postbacterial
infusion, complement is activated directly by the pathogen through
the classic, lectin, and alternative pathways. Because bacteria and
their pathogen-associated molecular patterns (e.g., LPS) are major
complement activators, this model is well suited for studying
C5 inhibition during the rapid progression of the bacteremic stage
of sepsis. This model allowed us to determine that early admin-
istration of a C5 inhibitor-attenuated disease progression, and
prevented multiple organ failure and death without affecting host
bacteria clearance.
Our study is not an exact mimic of a clinical model for sepsis
treatment in that we pretreated the animals with RA101295 1 h
before infusion of bacteria. This pretreatment was carried out to
allow absorption of the drug into the systemic circulation following
subcutaneous administration. Subcutaneous delivery allowed us to
maintain a therapeutic level of drug for 2 d without using in-
travenous infusion, which is not feasible in nonsedated animals. As
the pharmacokinetics properties of the drug become better
established, future studies should combine continuous infusion
of the drug during anesthesia with subcutaneous delivery during
postanesthesia.
Although our results clearly demonstrate that C5 inhibition
efficiently prevented organ damage and death, future studies are
Fig. 5. Effect of RA101295 treatment on blood cell counts and markers of
leukocyte activation. Time course changes of (A) hematocrit, (B) RBC,
(C) platelets, (D) leukocytes (WBC), (E) myeloperoxidase (MPO), (F) ICAM-3,
and (G) neopterin in the blood of septic baboons without (LD100) or
with treatment (LD100+RA101295). Data are presented as mean ± SEM (n =
5 per group). Same time-point data are compared between LD100 and
LD100+RA101295 using two-tailed Student t test: *P < 0.05, **P < 0.01,
***P < 0.001.
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needed to test if the therapy works in a postinfection model. The
in vitro data suggest that RA101295 can provide robust com-
plement inhibition even when the treatment is carried out
postinfection. However, delayed treatment cannot be tested in
high-load bacteremic challenge studies because the LD100
challenge leads to early, rapid, and irreversible organ damage as
a result of shock, DIC, and capillary leak. We also know from
other therapies tested in the LD100 model (28, 29) that the
chance of success decreases rapidly when the treatment is
delayed longer than 1 h postinfection. Experiments testing
delayed treatment with C5 inhibitor will likely require the use of
a less-severe challenge, such as an LD50 model, and will also
require a larger number of animals to achieve statistical signifi-
cance in determining survival benefit. It has been established that
the first 6 (“golden”) hours after the diagnosis of sepsis represent a
small but critical therapeutic window in which prevention of in-
flammation, coagulopathy, and complement-induced damage are
possible and during which progression to organ failure can be
averted. Thus, we regard C5 inhibitory treatment relevant only to
early stages of bacteremic sepsis, or even as a prophylactic in pa-
tients at high-risk of development of sepsis: for example, anasto-
mosis leakage after surgery or major burn and trauma patients.
We determined that RA101295 is an effective inhibitor of
complement activation. Treatment with RA101295 reduced the
level of sC5b-9 by over 99% and C5a by 90% in plasma at the
peak of bacteremia (T+2 h). Moreover, C3b levels were signifi-
cantly decreased in the treated group, suggesting that C5 blockade
prevented the C3 amplification loop that lies at the core of all
complement pathways (30). LPS is a known activator of the al-
ternative pathway; thus, the reduced C3b levels may also reflect
the lower amount of LPS released in the treatment group.
Complement blockade both at the C3 or C5 levels inhibited
the oxidative burst, a C5a-dependent process that leads to rapid
generation of peroxide, which is highly toxic for both pathogen
and host. Similarly, both the C3 and C5 inhibitors decreased the
explosive bacteriolysis associated with release of LPS, a process
induced by C5b-9. However, only C3 blockade diminished bac-
terial clearance by phagocytosis.
The in vitro data correlated well with in vivo results, where
treatment with RA101295 in septic baboons decreased bacteri-
olysis and LPS release but did not affect bacterial clearance.
Baboons challenged with E. coli and treated with RA101295
showed very low levels of live bacteria in their circulation after
6–8 h, whereas nontreated animals showed significant residual
cfu at 24 h postchallenge. The role of C5 in removal of bacteria
has not been clearly established. It has been suggested that
C5 deficiency increases the susceptibility to meningococcal in-
fections in humans (31), and C5 deficiency in mice is associated
with increased bacteremia in a CLP peritonitis model (32). In
vitro assays using whole blood from patients with C5 deficiency
suggested that C5 is essential for bacterial killing and that C5a is
required in bacterial phagocytosis and oxidative burst production
by up-regulating CR3 (CD11b/CD18) on leukocytes (33). Other
studies report that C5 inhibition with antibodies reduced the
bacterial load in the blood and organs and provided protection
against CLP-induced sepsis in rats with a genetic deficiency of
C6, which can generate C5a and C5b but not C5b-9 (18). Our
data showed that C5 inhibition decreased bacterial lysis and re-
duced the activation of neutrophils and monocytes, but did not
interfere with removal of bacteria by phagocytosis. The leuko-
cyte count in the blood of treated and nontreated animals
was decreased to a similar extent during the first 24–48 h de-
spite a significant decrease in C5a in the treated group, sug-
gesting similar levels of leukocyte margination and extravasation.
Fig. 7. Effect of RA101295 treatment on plasma markers of capillary leak
(A and B), liver (C), and endothelial cell (D and E) dysfunction. (A) Total proteins;
(B) albumin; (C) inter–α-trypsin inhibitor 4 (ITH4); (D) soluble uPAR; (E) soluble
thrombomodulin (s-TM); (F) Angiopoietin-2. Data are presented as mean ± SEM
(n = 5 per group). Same time-point data are compared between LD100 and
LD100+RA101295 using two-tailed Student t test: *P < 0.05, **P < 0.01.
Fig. 6. Treatment with RA101295 inhibits LPS release from lysed bacteria
without impairing bacteria clearance. (A) Time course of LPS in plasma,
quantified by using the HEK-Blue TLR4 reporting cells. Same time-point data
are compared between LD100 and LD100+RA101295 using two-tailed Student
t test: *P < 0.05, ***P < 0.001. (B) Time course of bacteremia as determined by
counting the colony forming units on agar plate. (C) Immunostaining of Lipid
A component of LPS in the lung from healthy (Control), septic treated (LD100+
RA101295), and septic not-treated (LD100) baboons. To better see the differ-
ence in fluorescence intensity between the three specimens, staining for lipid
A is shown in grayscale (Upper). (Lower) Samemicroscopic fields (lipid A in red)
are shown with nuclear counterstaining (blue). (Scale bars, 50 μm.)
(D) Quantitation of whole-field MFI of 20 images for each experimental con-
dition illustrated in C. ****P < 0.0001.



























Leukocyte counts gradually returned to normal in the animals
that survived.
Discrepancies between rodent peritonitis and our bacteremia
model could be because of the location of the pathogen. In our
model, bacteria are infused directly into the blood where they
are rapidly lysed, causing a massive release of proinflammatory
LPS into the systemic circulation. C5 inhibition blocks the
massive release of LPS and subsequent induction of proin-
flammatory cytokines and prothrombotic mediators, without af-
fecting bacterial clearance by phagocytosis. In the CLP model of
peritonitis, where the pathogen invades and proliferates in a
body cavity, lysis of the bacteria can lead to local rather than
Fig. 8. Effect of RA101295 on the histological changes of vital organs. (A) Histological images of organs collected at the time of necropsy stained with H&E.
(Scale bars, 100 μm.) (B) Semiquantitative evaluations of the pathological features performed in a blinded fashion and graded on a scale from 0 to 4, with
0 being normal and 4 being severe. Data are presented as mean ± SEM (n = 5). Data are compared between LD100 and LD100+RA101295 using two-tailed
Student t test. *P < 0.05, **P < 0.01.
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systemic release of LPS, and the lack of complement-mediated
lysis can promote the infection. It is plausible that the small
amounts of C5a produced in our treated animals was enough to
support phagocytosis-promoting signaling, whereas robust in-
hibition of the C5b-9 lytic complex decreased the amount of LPS
released by over 50% with potent antiinflammatory and organ
protective effects in septic baboons.
In a previous study, using the C3 inhibitor compstatin, we
successfully prevented multiple organ failure and markedly im-
proved blood pressure through blocking complement activation
in a less severely bacteremic (109 cfu/kg E. coli; LD50) model (15).
This study was limited to the first 24 h postchallenge and did not
monitor survival benefit. We also demonstrated that complement
activation products contribute to the fibro-proliferative response,
and we used pharmacological inhibition of complement to atten-
uate fibrosis, by decreasing the expression of several profibrotic
pathways, including TGF-β (34). The only E. coli sepsis study in
primates targeting C5a, using rabbit polyclonal antibodies, was
published three decades ago (17). Although showing attenuation of
lung dysfunction, and some systemic responses, this investigation
collected data for only 4 h postchallenge (17), therefore missing
information on long-term organ function and survival benefit.
RA101295 substantially decreased sepsis-induced coagulopathy.
The functions of complement and coagulation pathways in sepsis
are closely interlinked (13). C5a and C5b-9 increase the throm-
bogenicity of the blood by simultaneous induction of procoagulant
(35) and antifibrinolytic proteins, and inhibition of natural anti-
coagulants (5). C5b-9 induces (5) or decrypts tissue factor (36),
and induces exposure of phosphatidylserine on platelets to provide
a catalytic surface for prothrombinase (9, 10). C5a up-regulates
tissue factor and PAI-1 (37) on monocytes, thereby enhancing
blood thrombogenicity and decreasing dissolution of fibrin clots
(38). We previously demonstrated that C3 inhibition reduced
thrombocytopenia and microvascular thrombosis, and preserved
endothelial anticoagulant properties (15). Here we show that
C5 inhibition also substantially decreases the activation of both
intrinsic and extrinsic pathways of coagulation, as well as the fi-
brinolytic system in septic baboons. These data highlight the close
link between the coagulation and complement systems in sepsis
(13). Moreover, besides the pronounced antithrombotic effect,
our data demonstrate that C5 inhibition offers endothelial cell
protection, as revealed by the decrease in markers of endothelial
dysfunction (s-TM, s-uPAR, and angiopoietin-2).
RA101295 did not prevent the decrease in platelets and RBCs
induced by sepsis, suggesting that complement activation up-
stream of C5 contributes to platelet and RBCs clearance.
Platelets support complement activation, via CP, by binding C1q
through a specific receptor (39, 40), and they also bind C3b, a
major opsonin involved in the clearance of bacteria and dead
cells. Coating of platelets and RBCs with C3b and iC3b can
render them susceptible to phagocytosis by macrophages in the
spleen or liver. Indeed, we detected C3b on circulating aggre-
gates of platelets and bacteria in baboons challenged with E. coli,
suggesting that platelets and bacteria may be opsonized and
cleared together, by blood and tissue phagocytes. We and others
showed that C5b-9 deposition on platelets leads to platelet ac-
tivation and aggregation (9, 10). Future work should establish
the relative contribution of activated complement to platelet and
RBC clearance in sepsis.
Similar to C3 inhibition (15), blocking C5 ameliorated sepsis-
induced cardiomyopathy, one of the main predictors of poor
outcome in septic patients. C5a is a major cardio-depressant
(41). CLP sepsis in rodents induces expression of C5aR on car-
diomyocytes and increased generation of C5a causes dysfunction
of cardiomyocytes (42). Complement inhibition with compstatin
prevented sepsis-induced hypotension when administered at
T0 in the baboon LD50 model (15).
We observed that early C5 blockade significantly decreased
sepsis-induced inflammation. C5a is a strong inducer and en-
hancer of inflammation during sepsis (reviewed in ref. 38).
RA101295 significantly decreased the release of the proin-
flammatory LPS, substantially inhibited the production of proin-
flammatory cytokines, dampened plasma-activation markers of
neutrophils, and reduced leukocyte infiltration in vital organs.
Overall, the treatment provided significantly reduced mortal-
ity, as four of five baboons reached the 7-d end-point after
challenge with a bacterial dose that reproducibly leads to 100%
lethality within 24–36 h in untreated animals.
These results demonstrate that the complement system plays a
pivotal role in sepsis progression and offers proof-of-concept that
C5 inhibition can protect against organ damage and mortality.
Materials and Methods
Study Design. The objective of this study was to test whether inhibiting
complement function by preventing C5 cleavage protects against sepsis-
induced inflammation, consumptive coagulopathy, and organ failure, and
reduces mortality. We used well-established in vitro and in vivo models of
sepsis. The in vitro whole-blood sepsis model was used to investigate the
effect of the RA101295 C5 inhibitor on complement activation (C5a and sC5b-9
formation), bacteriolysis, and leukocyte functions, such as oxidative burst
and phagocytosis.
The in vivo effects of the C5 inhibitor on sepsis-induced complement ac-
tivation, inflammation, consumptive coagulopathy, organ functions, and
injury were studied in a LD100 baboon model of E. coli sepsis.
The Baboon Model of E. coli Sepsis. Our study was carried out in compliance
with the Animal Welfare Act, the Guide for the Care and Use of Laboratory
Animals (43), and the NIH Office of Laboratory Animal Welfare. The study
protocol received prior approvals by the Institutional Animal Care and Use
Committees of both the Oklahoma Medical Research Foundation and the
University of Oklahoma Health Science Center. The animals had free access
to water and primate diet; fruits and dietary enrichments were given during
the course of the study. Tuberculosis-free, healthy Papio anubis baboons,
males and females, 3–4 y old, 6–10 kg body weight, with hemoglobin
greater than 10 gm/dL and WBC counts less than 12,000 were included in the
study. Two experimental groups were studied: (i) E. coli challenge only (n =
5) and (ii) E. coli plus RA101295 treatment (n = 5). The group size was used
based on our previous experience (15) to account for biological variability
among animals and the need for reliable statistical analysis and balanced
ethical use of animals. Animals were sedated with ketamine (14–20 mg/kg,
intramuscularly), then pentobarbital (2 mg/kg, i.v.) was administered peri-
odically to maintain a light level of anesthesia during the experimental
procedure. Sepsis was induced by intravenous infusion of 1–2 × 1010 E. coli
(LD100 dose, serotype B7-086a:K61; ATCC) for 2 h. Blood samples and
physiological parameters were collected before the E. coli infusion (T0), then
after 2, 4, 6, and 8 h postbacterial challenge. The time after n hours of E. coli
infusion was referred as T+n h. Stock solutions of RA101295, (20 mg/mL)
were prepared in PBS, pH = 7. RA101295 (10 mg/kg body weight) was filter-
sterilized and subcutaneously injected at four time points: 1 h before the
Fig. 9. Effect of RA101295 on sepsis-induced mortality. Survival plot of
animals challenged with LD100 E. coli and treated with RA101295 (n = 5) vs.
control animals challenged with LD100 E. coli without treatment (n = 5).
Survival distribution of the two groups was determined using a log-rank
Mantel–Cox test; the result is significant at P = 0.0018.



























challenge, then at 8, 24, and 36 h after the E. coli challenge, based on the
bioavailability data obtained in pilot experiments (Fig. S1). Physiological
parameters, including mean systemic arterial pressure, heart rate, re-
spiratory rate, tissue oxygenation, and temperature, and blood samples
were collected during first 8 h as above, and then at 24, 48, and 72 h. Ani-
mals were continuously monitored during the study period and humanely
killed with Euthasol (50 mg/kg, i.v.) when the condition deteriorated or
when the animals reached the primary end-point (7-d survival).
The primary end-point was prospectively selected based on extensive pre-
vious experience with this model (2). RA101295-treated animals that survived
for 7 d after E. coli challenge reached the primary end-point of the study. To
reduce the number of animals used, the study was stopped when statistical
significance of the primary end-point (P < 0.005 Mantel–Cox test when com-
pared survival between treated vs. nontreated controls) was achieved.
At the end of the experiment, animals were killed and tissue samples were
snap-frozen in liquid nitrogen and stored at −80 °C or fixed in 4% para-
formaldehyde for microscopy (15).
Biochemical Assays. Lactate level was measured by Lactate Scout (EKF Di-
agnostics). Serum metabolites (BUN, creatinine, albumin, total proteins, and
alanine aminotransferase) were measured by using a comprehensive di-
agnostic profile rotor and VetScan VS2 (Abaxis Veterinary Diagnostics)
chemistry analyzer.
ELISA. Plasma cytokine levels were measured using the MILLIPLEX MAP Non-
Human Primate Cytokine Magnetic Bead Panel (EMD Millipore) as per the
manufacturer’s instructions. The complement activation product sC5b-9 was
measured as described previously (44). Briefly the monoclonal antibody aE11
(Enzo Life Sciences), which binds to a neoepitope exposed in C9 after in-
corporation in the C5b-9 complex, was used as capture antibody. Anti-human
C6 biotinylated antibody (Quidel) was used as detection antibody. Pooled
human serum activated with heat-aggregated IgG (1 mg/mL) and zymosan
(10 mg/mL) containing 1,000 CAU/mL of C5b-9, was used as standard (44). C5a
was measured by using mouse anti-human C5a/C5a(desArg), clone 17/5 cap-
ture antibody (BioLegend) and biotinylated anti-human C5a/C5a(desArg)/C5,
clone G25/2 detection antibody (BioLegend). Zymosan-activated (10 mg/mL)
baboon serum containing 1,000 CAU/mL C5a was used as standard (44). C3b/c
was measured using mouse monoclonal anti-human C3b/c IgG, clone C3-28,
which recognize a neoepitope not exposed in native C3 (Cell Sciences), for
capture, and goat anti human C3 (Complement Technologies) as detection
antibody. Purified C3 protein (Complement Technologies) was used as stan-
dard. TAT complex was measured using the Enzygnost-TAT ELISA kit
(Siemens). Inhibitory complexes of Factor XIa and Factor VIIa with anti-
thrombin were detected by sandwich ELISA, in which affinity-purified goat
polyclonal antibodies against human Factor XI or Factor VII were used for
antigen capture and biotinylated goat polyclonal antibodies against human
antithrombin (all from Affinity Biologicals) and Streptavidin- peroxidase for
detection. For these two assays, optical density values were reported as a
percentage of T0. Kits for soluble thrombomodulin, ICAM-3, PAI-1, and uPAR
were from R&D Systems; neopterin from Immune-Biological Laboratories;
D-dimer from Diagnostica Stago; and PAP from Technoclone. All assays were
performed according to manufacturers’ instructions.
Coagulation Tests. APTT and PT were measured as described previously (15).
FDP were measured by latex agglutination assay (45). Fibrinogen concen-
tration was determined using a clotting based functional assay (45).
Myeloperoxidase Activity Assay. Myeloperoxidase in plasma samples was de-
termined by using FluoroMPOmyeloperoxidase detection kit (Cell Technology)
as per the manufacturer’s instructions.
Cell-Based Assay for LPS. HEK-Blue hTLR4 cells (InvivoGen) were cultured in
DMEM, 4.5 gm/L glucose, 10% (vol/vol) FBS, 50 U/mL penicillin, 50 μg/mL
streptomycin, 100 μg/mL normocin, 2 mM L-glutamine and 1× HEK blue se-
lection medium (InvivoGen). Baboon plasma was diluted in PBS and in one
sample polymyxin B was added (10 μg/mL). LPS from E. coli, serotype O55:B5
S-form was used as standard. HEK-Blue hTLR4 cells were suspended in HEK-
Blue detection medium to measure alkaline phosphatase secreted in the
medium. Twenty microliters of LPS or diluted plasma was added to the re-
spective well of a 96-well plate, and then 180-μL cell suspensions were
added. The plate was incubated at 37 °C in 5% CO2 incubator for 12–14 h.
Absorbance was recorded at 620–650 nm.
Morphologic Analysis. For immunofluorescence, tissues were fixed in 4%
paraformaldehyde, washed in 15% sucrose/PBS, embedded in OCT, snap-
frozen in liquid nitrogen, and stored at −80 °C.
Cryosections (∼10 μm) were incubated with primary antibodies: goat anti-
LPS (Meridian Life Sciences); mouse monoclonal anti C3b/c, clone C3-28 (Cell
Sciences); monoclonal anti C5b-9 neoepitope, clone aE11 (Enzo Life Sci-
ences), overnight at 4 °C, followed by appropriate detection antibodies
coupled to FITC or Cy3 and mounted with VectaShield hardset mounting
medium (Vector Laboratories) supplemented with ToPro3 (Invitrogen) as
nuclear counterstaining (15, 46).
Histopathologic analysis was done on paraffin sections stained with
phosphotungstic acid, Prussian blue, or H&E by an experienced veterinary
pathologist (S. Kosanke, Oklahoma University Health Sciences Center,
Oklahoma City, OK), who was blinded to the experimental conditions (45).
In Vitro Whole-Blood Model Incubated with E. coli. Blood was collected from
consenting healthy volunteers in polypropylene tubes containing lepirudin
(50 μg/mL blood), a thrombin inhibitor that does not interfere with the
complement activation (23). Whole blood was preincubated with vehicle,
RA101295 (1 μM; Ra Pharmaceuticals) or Compstatin (0.2 mg/mL; Tocris
Bioscience) for 20 min and then incubated with E. coli (5 × 107 cfu/mL) for
30 min. In a different set of experiments, RA101295 (1 μM) was added at 0, 5,
15, 30, or 60 min after E. coli (5 × 107 cfu/mL) inoculation to lepirudin-
anticoagulated baboon blood, to determine the effect of posttreatment
on complement activation. For the complement assay, 10 mM EDTA was
added to stop further activation and samples were centrifuged at 3,500 × g
for 15 min at 4 °C. Plasma was stored at −80 °C until further analysis (23).
Phagocytosis Assay. Lepirudin-anticoagulated whole blood was preincubated
with RA101295 (1 μM), then treated with FITC labeled E. coli for 30 min. RBCs
were lysed using 1× RBC lysis buffer (150 mM ammonium chloride, 10 mM
sodium bicarbonate, 0.1 mM EDTA). Leukocytes were resuspended in ice-cold
1% PFA-PBS and analyzed on FACS Calibur flow cytometer (BD Biosciences).
Monocytes and neutrophils were gated on the basis of side scatter and forward
scatter. To differentiate between phagocytized and adherent bacteria, Trypan
blue (250 μg/mL) was added and samples were read within 2 min. Mean fluo-
rescence intensity of E. coli challenged sample was considered as 100%.
Oxidative Burst Assay. Lepirudin anticoagulatedwhole bloodwas preincubated
with RA101295 (1 μM) and then treated with E. coli (5 × 107 cfu/mL) for 15 min.
Free-radical binding dye DHR 123 (10 μM) was added to each tube and in-
cubated for 15 min. RBCs were lysed and samples were measured using a flow
cytometer as described above. Mean fluorescence intensity (MFI) of E. coli
challenged sample was considered as 100%.
Statistical Analysis. For statistical analyses, we used Prism (GraphPad Software
6.0b). Values are given as mean ± SEM. Comparisons between two groups
were performed using a two-tailed Student t test and multiple comparisons
were made by one-way ANOVA followed by Bonferroni post hoc test. Re-
sults were considered significant at P < 0.05 (*P < 0.05, **P < 0.01, ***P <
0.001). Comparison of survival data were done using log-rank Mantel–Cox
test. P value tests the null hypothesis that the survival curves are identical in
the two groups (the treatment did not change survival). Results obtained
were significantly different at P = 0.0018.
Data reported in this article were presented in abstract form at two annual
meetings of the American Society of Hematology (47, 48). RA101295 can be
obtained from Ra Pharmaceuticals through a material transfer agreement.
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